Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Michele Magni et al.|Journal of Clinical Oncology|2010Cited by 167
HER2 intratumoral heterogeneity predicts response to neoadjuvant therapy in HER2-positive breast cancer: impact and interplay with HER3 expressionAngela Santoro, Antonino Mulè|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2025Cited by 0